Response to biologic therapy in Crohn's disease is improved with early treatment: An analysis of health claims data

Inflammatory Bowel Diseases

Volumn 18, Issue 12, 2012, Pages 2225-2231

  Rubin, David T ^a   Uluscu, Ozgecan ^b   Sederman, Robert ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b C1 Consulting Summit   (United States)

Author keywords

inflammatory bowel disease; top down; tumor necrosis factor

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; CORTICOSTEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CONTROLLED STUDY; CROHN DISEASE; DATA ANALYSIS; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84869221091     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22925     Document Type: Article

References (29)

1. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010; 138: 463-468.
2. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-1395.
3. D'Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371: 660-667.
4. Panaccione R, Rutgeerts P, Sandborn WJ, et al. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008; 28: 674-688.
5. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992; 339: 89-91.
6. Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet. 1999; 353: 459-461.
7. Danese S,. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. Dig Liver Dis. 2008; 40 Suppl 2: S225-S228.
8. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2010; 16: 112-124.
9. Lichtenstein GR, Hanauer SB, Sandborn WJ,. Management of Crohn's disease in adults. Am J Gastroenterol. 2009; 104: 465-483.
10. Pache I, Rogler G, Felley C,. TNF-alpha blockers in inflammatory bowel diseases: practical consensus recommendations and a user's guide. Swiss Med Wkly. 2009; 139: 278-287.
11. Sadowski DC, Bernstein CN, Bitton A, et al. Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol. 2009; 23: 185-202.
12. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65.
13. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
14. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130: 323-333.
15. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008; 6: 644-653.
16. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357: 228-238.
17. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005; 129: 807-818.
18. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357: 239-250.
19. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337: 1029-1035.
20. Meier J, Sturm A,. Concomitant use of immunomodulators with anti-TNF in Crohn's disease: yes or no? Curr Drug Targets. 2010; 11: 176-178.
21. van der Woude CJ, Hommes DW,. Are we ready for top-down therapy for inflammatory bowel diseases: pro. Expert Rev Gastroenterol Hepatol. 2007; 1: 243-248.
22. Martins NB, Peppercorn MA,. Inflammatory bowel disease. Am J Manag Care. 2004; 10: 544-552.
23. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005; 54: 237-241.
24. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008; 135: 1493-1499.
25. Pedersen N, Duricova D, Lenicek M, et al. Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients. Eur J Gastroenterol Hepatol. 2010; 22: 1196-1203.
26. Jones DW, Finlayson SR,. Trends in surgery for Crohn's disease in the era of infliximab. Ann Surg. 2010; 252: 307-312.
27. Lazarev M, Ullman T, Schraut WH, et al. Small bowel resection rates in Crohn's disease and the indication for surgery over time: experience from a large tertiary care center. Inflamm Bowel Dis. 2010; 16: 830-835.
28. Picco MF, Zubiaurre I, Adluni M, et al. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease. Am J Gastroenterol. 2009; 104: 2754-2759.
29. Ramadas AV, Gunesh S, Thomas GA, et al. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut. 2010; 59: 1200-1206.